Aura Biosciences announced that 2-year clinical data from its ongoing phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the company’s lead product candidate for the treatment of primary choroidal melanoma, will be highlighted in an oral presentation at the American Society of Retina Specialists (ASRS) being held July 26-30, 2019 in Chicago.
“There is an urgent unmet medical need for targeted treatment options for patients suffering from primary choroidal melanoma, a life-threatening form of eye cancer,” Amy C. Schefler, MD, Associate Professor of Clinical Ophthalmology, Weill Cornell Medical College/Houston Methodist Hospital and the University of Texas Health Science Center, said in a company news release. “Emerging results from the phase 1b/2 trial of light-activated AU-011 demonstrate tumor control and visual acuity preservation, warranting continued development of the program.”
Title: Two-Year Results of an Ongoing Phase 1b/2 Open Label Clinical Trial of AU-011 for the Primary Treatment of Small to Medium Choroidal Melanoma
Presenter: Amy C. Schefler, MD, Associate Professor of Clinical Ophthalmology, Weill Cornell Medical College/Houston Methodist Hospital and the University of Texas Health Science Center
Session: Ocular Oncology Symposium
Date and time: Monday, July 29, 2019; 9:35-9:41am CDT